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e bile acid analogue [18F]LCATD (LithoCholic Acid Triazole Derivative) is transported in vitro by hepatic uptake transporters
such as OATP1B1 and NTCP and eux transporter BSEP. In this in vivo “proof of principle” study, we tested if [18F]LCATDmay be
used to evaluate drug-drug interactions (DDIs) caused by inhibition of liver transporters. Hepatic clearance of [18F]LCATD in rats was
signicantlymodied upon coadministration of rifamycin SV or sodium fusidate, which are known to inhibit clinically relevant uptake
transporters (OATP1B1, NTCP) and canalicular hepatic transporters (BSEP) in humans. Treatment with rifamycin SV (total dose
62.5mg·Kg−1) reduced the maximum radioactivity of [18F]LCATD recorded in the liver from 14.2± 0.8% to 10.2± 0.9% and delayed
t_max by 90 seconds relative to control rats. AUCliver 0–5min, AUCbile 0–10min and hepatic uptake clearance CLuptake,in vivo of rifamycin SV
treated rats were signicantly reduced, whereas AUCliver 0–30min was higher than in control rats. Administration of sodium fusidate
(30mg·Kg−1) inhibited the liver uptake of [18F]LCATD, although to a lesser extent, reducing the maximum radioactivity in the liver to
11.5± 0.3%.ese preliminary results indicate that [18F]LCATDmay be a good candidate for future applications as an investigational
tracer to evaluate altered hepatobiliary excretion as a result of drug-induced inhibition of hepatic transporters.
1. Introduction
Hepatocytes perform most of the liver functions and are
responsible for the detoxication of exogenous substances,
including drug elimination through metabolism and/or
biliary excretion processes. Drugs that cannot passively
cross the lipid core of the hepatocyte membrane can be
actively transported into hepatocytes by uptake transporter
proteins. Within the hepatocyte, drugs may undergo
metabolism and their metabolites may be transported by
eux transporters, either back into blood by basolateral
eux transporters or excreted into bile by canalicular
transporters. Drugs and/or drug metabolites can competi-
tively inhibit hepatic transporters, leading to pharmacokinetic
interactions with coadministered drugs (or drug-drug-
interactions, DDIs) that may result in serious adverse e¥ects
due to reduced drug clearance or intracellular accumulation
of these drugs or their metabolites in hepatocytes [1, 2].
With the aim to detect DDIs at an early stage of drug
development and increase the understanding of hepatobiliary
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transport and its perturbation by action of clinically used
drugs in vivo, considerable e¥orts have been dedicated to
develop PET tracers for the study of hepatic transporters
[3–5]. In this context, we previously described a lithocholic
acid derivative, [18F]LCATD (Figure 1), which is a promising
PET tracer to study the potential of clinically used drugs for
hepatic transporter-mediated DDIs and hepatotoxicity [6]. In
vitro studies conrmed that [18F]LCATD appears to be
a substrate of membrane uptake transporters OATP1B1 and
NTCP (while being a low a©nity substrate of OATP1B3) and
is excreted into the bile via the eux transporter BSEP. [18F]
LCATD is characterized by low passive permeability and, as
demonstrated by a preliminary imaging experiment in rats, it
rapidly accumulated into the liver to be then excreted ex-
clusively into the bile [6].
Here, we present the results of preclinical PET imaging
studies performed to assess the potential of [18F]LCATD to
image in vivo the e¥ects of rifamycin SV and sodium fusidate
on hepatic uptake and biliary excretion when coadministered
via bolus injection. In vitro studies conrmed earlier that [18F]
LCATD acts as a probe for endogenous bile acid transport and
can be used for preclinical evaluation of drug interference at
the level of hepatic bile acid transporters function. Although in
vitro assays were performed in cells expressing human
OATP1B1, we chose the rat model for our investigations as the
human and the rat orthologs of OATP1B1 exhibit very similar
transport characteristics. Furthermore, rats have been used
extensively as animal models for studies on liver transporters
[3, 4, 7] and for the evaluation of transporters targeting PET
tracers, such as [11C]dehydropravastatin [8], [11C]rosuvastatin
[7], [11C-]telmisartan [9], [11C]N-acetyl leukotriene E4 [10],0
and (15R)- 16-m-[11C]tolyl-17,18,19,20-tetranorisocarbacyclin
methyl ester [11].
2. Materials and Methods
2.1. Chemicals and Radiotracer. For preclinical PET studies,
[18F]LCATD was synthesised as reported previously [6] (see
the Supplementary Materials for further details) and for-
mulated in 10% ethanol in PBS. Radiochemical purity was>99% and specic activity >20GBq·µmol−1. Rifamycin SV
was purchased from Sigma Aldrich (UK) and dissolved in
10% ethanol in saline solution (20mg·mL−1). Sodium
fusidate was purchased from Sigma-Aldrich (UK) and was
formulated in saline solution (20mg·mL−1).
2.2. Animals. Female Sprague-Dawley (SD) rats (200–250 g)
were purchased fromHarlan (UK).e animals were provided
with standard food and water at libitum in a temperature and
light-controlled environment. All animal experiments were
performed according to the Aberdeen University’s Code of
Practice on the Use of Animals in Research as well as the legal
requirements of the Animals (scientic procedures) Act 1986
and Home O©ce Code of Practice guidance. At the end of the
imaging experiments, animals were culled by cardiac puncture
(schedule 1 technique, exsanguination) while under anaes-
thesia, and then a terminal blood sample, liver, kidney, and
heart were collected.
2.3. PET/CT Imaging. PET scans were performed with
a preclinical PET/CT SEDECAL ARGUS scanner (SEDE-
CAL, Spain) housed in a temperature-controlled suite. e
scanner has two 11.8 cm diameter rings of photoswitch
detectors coupled to position-sensitive photomultiplier
tubes, giving a 4.8 cm axial and 7.5 cm transaxial eld of view
(FOV). All animals were cannulated (Venisystem Butter±y,
Abbott Ireland) in the tail vein for tracer injection under
general anaesthesia with iso±urane (IsoFlo 100% w/w,
Abbott Laboratories Ltd) 2.5% (2 L·min−1 oxygen ±ow).
Animals were divided into three groups: control group
(administered with [18F]LCATD only, 3 animals), rifamycin
SV-treated group (3 animals) and fusidate-treated group
(3 animals). All the animals were scanned in supine position.
At the start of the scan, [18F]LCATD (5–15MBq per body)
was injected as a single bolus into the tail vein. Administered
radioactivity was measured as the net counts in the syringe
before and after the injection with an ionization chamber
(Capintec CRC-15PET; Ramsey, New Jersey). e mass
amount of [18F]LCATD administered per animal was esti-
mated to be between 0.2 and 1 nmol. For inhibition experi-
ments, rifamycin SV was administrated 45 minutes before the
start of the scan at a dose of 50mg·Kg−1 (intraperitoneally) and
at the time of the tracer injection at a dose of 12.5mg·Kg−1
(intravenously). For the in vivo assessment of the inhibitory
e¥ect of sodium fusidate on the hepatobiliary transport of the
tracer, the drug was administrated at a dose of 20mg·Kg−1
(intraperitoneally) 30 minutes before the scan and at a dose of
10mg·Kg−1 (intravenously) after 15 minutes from the tracer
injection. Emission scans in 3D list-mode were acquired for
30 minutes (with a FOV encompassing part of the thorax
and the intestine) followed by a 5 minutes CT scan. PET
acquisitions were obtained with an energy window set to
250–700 keV and corrections for dead-time, activity decay,
attenuation, random, and scatter counts were applied (using the
manufacturer’ software).e dynamic images were obtained
by sorting the list mode data into the following time frames:
6×10 s, 8× 30 s, 10× 60 s, and 3× 300 s, and images were
reconstructed with a FORE/2D-OSEM reconstruction algo-
rithm (provided by the manufacturer). Sampling at shorter
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Figure 1: Chemical structure of [18F]LCATD.
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intervals during early time-points enabled us to detect rapid
increments of tracer uptake in the liver and intestine. Longer
time frames at later time-points from the injection time re-
duced noise in the images and showed the amounts of uptake
characteristic for the speciﬁc PET tracer. A 5-minute PET
scan of the injection site at the end of the CT was obtained
to ensure successful intravenous injection. Cross calibration
between the ionization chamber and the PET scanner was
carried out by using a cylindrical phantom made of Perspex
with internal diameter of 43mm and length of 37mm. 10 to
20 minute PET scans of the phantom ﬁlled with an average
of about 4.20MBq of [18F]LCATD in 60 g of water were ac-
quired (average dead-time value 4%).
,e registered PETand CT images were transferred from
the scanner to a processing workstation, and subsequent
analysis was carried out using Pmod (Pmod Technologies,
CH) version 3.2. Regions of interest (ROIs) corresponding to
abdominal aorta, liver, and gastrointestinal tract were de-
ﬁned via a combination of manual and threshold methods
(Supplementary Figure 1 and movie) using PMOD software
(PMOD Technologies). ,e stomach was included in the
gastrointestinal ROI to include the amount of bile that might
have reﬂuxed from the duodenum into the stomach.
2.4. PostmortemBiodistribution of the Tracer. Samples of the
liver, heart, and kidney were collected at the end of the PET-
CT scan (after euthanasia) and homogenised with methanol
(80% in water, 5mL per gram of biological sample) by means
of a homogenizer. Samples were stored in preweighed plastic
vials. Terminal blood was collected by cardiac puncture just
before euthanasia. ,e activity of the homogenates and
blood samples was measured by means of a precalibrated
gamma counter as soon as possible after the PETexperiment.
2.5. Postmortem Metabolites Analysis. Analysis of metabo-
lites in the blood, liver, and bile (extracted from the in-
testine) was performed via radio-HPLC. Blood samples,
collected by cardiac puncture at the end of the PET-CTscan,
were treated with an equal volume of acetonitrile, centri-
fuged for 1 minute at 1000 rpm and the supernatant was
injected in radio-HPLC (Shimadzu Prominence HPLC
system equipped with a PDAUV detector and HERMLB500
activity detector and Phenomenex Luna C18 column, 5 μm,
100 A˚, 250× 4.6mm, injection volume 20 µL, PBS/CH3CN
60 : 40, isocratic elution, ﬂow: 1mL·min−1). Samples of the
liver and duodenumwere collected at the end of the PET-CT
scan (after euthanasia) homogenated with methanol (80% in
water, 5mL per gram of biological sample) by means of
a homogenizer and centrifuged for 1minute at 1000 rpm and
the supernatant was injected in radio-HPLC.
2.6. Data Analysis. Uptake hepatic clearance CLuptake,in vivo
was calculated by integration plots obtained applying the
Patlakmethod in Pmod (Pmod Technologies, CH) version 3.2,
limiting the linear ﬁt to the uptake phase (0–3min) [3, 12].
Intrinsic biliary clearance of the radiotracer CLint,bile was
determined as proposed by Takashima et al. [11] by
quantiﬁcation of the radiotracer in the liver and the intestine
(as amount of radiotracer excreted into the bile).
An ANOVA single-factor analysis (Microsoft Excel
2013) was used to check whether there were statistically
signiﬁcant diﬀerences between AUC of blood, liver, and bile
of three groups (control, rifamycin, and fusidate treated
rats). For AUCliver, there was a statistically signiﬁcant dif-
ference between groups, p � 0.01; for AUCblood, there were
no statistically signiﬁcant diﬀerences between group means,
p � 0.7; for AUCbile, there was a statistically signiﬁcant
diﬀerence between groups, p � 0.03.
Two-tailed Student’s t-test (Microsoft Excel 2013) with
equal variances was used to determine level of signiﬁcance of
various PK parameters between control and drug-treated
animals at various time periods.
3. Results
3.1. Concentration Proﬁles of [18F]LCATD in Arterial Blood.
,e PET tracer concentration in arterial blood was derived
from the PET images by observing the activity of a clearly
visible portion of the abdominal aorta (Figure S4, Supple-
mentary Materials). ,e image-derived arterial concentra-
tion of the PET tracer is likely to be aﬀected by errors due to
the small dimensions of the blood vessel in comparison to
the scanner’s spatial resolution. Indeed, contamination due
to spillover from other vicinal organs and partial volume
eﬀects are expected to increase and reduce respectively (by
unknown amounts) the actual activity of the arterial blood.
However, most of these eﬀects should be similar among
diﬀerent animals, allowing the comparison between treated
and untreated groups.
,e blood time-activity curves (TAC) obtained for
control, rifamycin SV-treated and fusidate-treated animals
are reported in Figure 2(a). ,e blood concentration of the
tracer in rifamycin SV-treated animals was higher than
the PET tracer concentration measured in control rats, but
the diﬀerences between the relative TAC curves were not
signiﬁcant (for clarity the standard deviation bars are not
shown in Figure 2(a)). ,e blood concentration of the tracer
in fusidate-treated animals was instead lower than the PETtracer
concentration measured in the blood of control rats, but again
the diﬀerences between the relative TACs were not signiﬁcant.
3.2. Liver Uptake and Biliary Eﬄux of [18F]LCATD.
Coronal representative PET images of the liver of control,
rifamycin SV-treated, and fusidate-treated rats are reported in
Figure 3. Reduced exposure to radioactivity in the liver of
rifamycin SV-treated rats as well as delayed biliary excretion of
the tracer can be clearly observed, whereas no obvious diﬀer-
ences can be noticed between control and fusidate-treated rats.
TAC for the liver of control, rifamycin-treated, and
fusidate-treated rats are shown in Figure 2(b). In control
rats, a maximum of 14.2± 0.8% of the injected dose was
found in the liver 150 seconds postinjection. Rapid washout
was observed, and after 30 minutes, the residual activity
measured in the liver was 1.04± 0.17% of the injected dose.
In rifamycin SV-treated rats, the maximum activity recorded
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in the liver was 10.2± 0.9% of the injected dose 225 seconds
postinjection. e washout phase was clearly delayed, and
after 30 minutes, the activity in the liver was 1.87± 0.13% of
the injected dose. Treatment with sodium fusidate reduced
the maximum activity registered in the liver to 11.5± 0.3% of
the injected dose 135 seconds after tracer injection.e TAC
prole was similar to the one obtained for control rats, with
a fast washout that reduced the activity in the liver to 1.02±
0.02% of the injected dose after 30 minutes (Table 1).
Quantitative PET analysis showed that the activity found in
the liver 2 minutes after tracer injection in control, rifamycin
SV-treated, and fusidate-treated rats (Figure 2(d)) is sig-
nicantly di¥erent among the groups (p< 0.05). At this
time-point, 14.2± 0.8% of the injected activity was found in
the liver of control rats, while for the rifamycin SV-treated
and sodium fusidate-treated rats, the liver activity was re-
duced to 8.0± 0.6% and 11.4± 0.4% respectively.
e area under the curve for the liver from 0 to 5minutes
(AUCliver 0–5min) for rifamycin SV-treated rats was signi-
cantly lower than that of control rats, and the same observation
can be made for the AUCliver 0–5min of fusidate-treated rats,
while no statistically signicant di¥erence was found between
the liver AUCliver 0–30min of the three animal groups (Table 1).
In order to calculate the liver uptake clearance CLuptake,in vivo,
integration plots were obtained applying the Patlak method
in Pmod, limiting the linear t to the uptake phase [3].
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Figure 2: (a) Time-activity proles obtained from the images of the abdominal aorta of control, rifamycin SV-treated, and fusidate-treated
rats. No statistical signicance of rifamycin-SV and fusidate-treated rats compared to the control was found at any point (error bars omitted
for clarity). (b) Time-activity proles obtained from the images of the liver of control, rifamycin SV-treated, and fusidate-treated rats as
mean ±1 s.d., n  3. (c) Time-activity proles for the bile, obtained from the images of the gastrointestinal region of control, rifamycin SV-
treated, and fusidate-treated rats as mean ±1 s.d., n  3. (d) Activity in the liver of control, rifamycin SV-treated, and fusidate-treated rats at
2 minutes postinjection determined noninvasively via PET imaging, as mean ±1 s.d., n  3. Statistical signicance of rifamycin-SV and
fusidate-treated rats compared to the control was assessed by two-tailed t-test assuming equal variances, ∗p< 0.05.
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In this study, the blood time-concentration input function
was derived from [18F]LCATD’s activity in the abdominal
aorta; therefore, CLuptake,in vivo values so calculated cannot
be compared with those obtained for di¥erent tracers from
literature, whose blood concentrations were determined by
measuring the activity of blood samples [3].eCLuptake,in vivo
of rifamycin SV-treated and fusidate-treated rats were
signicantly lower than the CLuptake,in vivo of control rats
(Table 1).
As shown by the bile TACs reported in Figure 2(c), the
radiotracer’s biliary excretion was delayed in rifamycin SV-
treated and fusidate-treated rats, while for control rats,
a straight line was observed between 0 and 200 seconds and
a plateau was observed in the case of the drug-treated rats.
e area under the curve for the bile from 0 to 10 minutes
(AUCbile 0–10min) of rifamycin SV-treated rats was signi-
cantly lower than the one obtained for control rats, whereas
no di¥erence was found among control and fusidate-treated
rats. Di¥erences in the intrinsic biliary clearance of the
radiotracer CLint,bile [3] were found not to be statistically
signicant between control and rifamycin SV-treated rats,
whereas sodium fusidate treatment signicantly increased
this value (Table 1).
3.3. PostmortemBiodistribution of the Tracer. Activity found
in the liver of control, rifamycin SV-treated, and fusidate-
treated animals 50 minutes postinjection was extremely low
(Figure 4), as expected from the fast clearance previously
observed for the tracer, and no statistically signicant
(a)
2 min 4 min 8 min
4 min 8 min2 min
(b)
4 min 8 min2 min
(c)
0 % ID (mL) 30
Figure 3: Maximum intensity coronal projection of livers of a representative control (a), rifamycin SV-treated (b), and fusidate-treated
(c) rat at 2, 4, and 8 minutes postinjection.
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di¥erences were found among the three experimental
groups. Neither rifamycin SV nor sodium fusidate signi-
cantly a¥ected the biodistribution of the tracer in kidneys 50
minutes postinjection, which was extremely low in all the
animal groups. In fact, the renal clearance of [18F]LCATD
appears negligible if compared with the biliary clearance, as
kidneys were not visible in the PET scan images, despite
being in the eld of view. Both rifamycin SV and sodium
fusidate signicantly increased the activity in the terminal
blood sample, and higher levels of radioactivity were found
in the heart of treated animals. is is consistent with
a reduced liver uptake and excretion, which are both ex-
pected to increase the PET tracer’s blood concentration.
4. Discussion
e PET tracer [18F]LCATD is a bile acid analogue, closely
related to lithocholic acid, that can be used as a probe to
evaluate the inhibition of liver transporters. In vitro cell
uptake and membrane vesicle eux assays using [3H]
LCATD demonstrated that this amphiphilic molecule can
hardly penetrate the cell membrane by passive di¥usion,
whereas it is quickly taken up by cells expressing the
OATP1B1, NTCP transporters, and euxed by means of
BSEP [6]. Involvement of other uptake transporters
(e.g., OATP2B1, OATP1A2, OAT2, and OAT7) and apical
transporters (such as MATE1, MRP2, BCRP, and MDR1/3)
could not be excluded. A preliminary in vivo PET study
showed that, after intravenous injection, [18F]LCATD se-
lectively accumulates in the liver [6], the sole organ in which
the murine homologs of such transporters are signicantly
expressed.
Being [18F]LCATD a substrate of the pharmacologically
relevant hepatic transporter OATP1B1, as well as of
transporters that are normally involved in the uptake and
clearance of bile acids (such as NTCP and BSEP), if the
coadministration of a drug a¥ects the biodistribution of
[18F]LCATD, then there are high chances that the drug
could cause DDIs or possibly drug induced hepatoxicity. As
a preclinical proof of concept, this study was focused on the
e¥ects of the coadministration of two drugs known to inhibit
hepatic transporters, for example, rifamycin SV and sodium
fusidate, on the hepatobiliary distribution of [18F]LCATD.
Rifamycin SV has been widely used in vitro as a pharma-
cologically relevant transporter inhibitor [13–16], and we
have previously demonstrated that it could inhibit the up-
take of tritium-labelled LCATD in an OATP1B1 cell-based
assay [6]. We therefore anticipated that rifamycin SV could
represent a benchmark inhibitor for this imaging study. On
the other hand, sodium fusidate was selected as transporters
inhibitor for this study because of its involvement in clin-
ically relevant DDIs. Fusidate-induced hepatic transporters
inhibition has indeed been proposed as a possible cause of
myopathy including rhabdomyolysis upon coadministration
with statins [17, 18].
To date, a small number of bile acids derivatives la-
belled with gamma and positron emitting radioisotopes
have been developed with the aim of studying hep-
atobiliary and intestinal transport by means of SPECT and
PET imaging. [75Se]25-homotaurocholic acid (SeHCAT)
[19] was the rst gamma-emitting bile acid derivative,
developed in 1979. [11C]Cholylsarcosine, an analogue of
the bile acid cholylglycine rstly reported in 2012 [20], has
been shown to be transported by bile acid transporters in
Table 1: Kinetic parameters for [18F]LCATD as mean ±1 s.d., n  3.
Group t_max(s)
Cmax,liver
(% ID·mL−1) AUCliver 0–5min(% ID·min·mL−1) Kp liver0−5min AUCliver 0–30min(% ID·min·mL−1) AUCbile 0–10min(% ID·min·mL−1) CLuptake,in vivo(mL·min−1·g−1) CLint,bile(mL·min−1·g−1)
Control 135 14.3± 0.9 58± 1 3.64± 0.09 110± 15 89± 1 2.09± 0.27 0.17± 0.03
Rifamycin
SV-treated 225 10.2± 0.9∗ 44± 4∗ 2.07± 0.17 139± 9 53± 3∗ 0.71± 0.05∗ 0.12± 0.03
Fusidate-
treated 135 11.5± 0.3∗ 48± 0.3∗ 2.451±0.016 89± 11 93± 19 1.40± 0.13∗ 0.36± 0.03∗
Statistical signicance of rifamycin-SV and fusidate-treated rats compared to the control was assessed by two-tailed t-test assuming equal variances, ∗p< 0.05.
tmax: time to maximum peak concentration; Cmax,liver: maximummeasured activity in the liver; AUCliver 0–5min: area under the curve for the liver from 0 to
5 minutes postinjection; Kp liver 0–5min: apparent liver-to-blood AUC0–5min ratio; AUCliver 0–30min: area under the curve for the liver from 0 to 30
minutes postinjection; AUCbile0–10min: area under the curve for the bile (as radioactivity measured in the gastrointestinal tract) from 0 to 10 minutes
postinjection; CLuptake,in vivo:in vivo uptake clearance; CLint,bile: intrinsic biliary clearance of the radiotracer.
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Figure 4: Activity in the liver, kidney, heart, and blood of control,
rifamycin SV-treated, and fusidate-treated rats at 50 minutes
postinjection as mean ±1 s.d., n  3. Statistical signicance of
rifamycin-SV and fusidate-treated rats compared to the control was
assessed by two-tailed t-test assuming equal variances, ∗p< 0.05.
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pigs [21] and proved to be a useful PET tracer to study
biliary secretion in healthy humans and patients with
cholestasis [22]. Soon after our ﬁrst report of [18F]LCATD
as the ﬁrst [18F]ﬂuorine-labelled bile acid [6], another
derivative of cholic acid, 3β-[18F]ﬂuorocholic acid ([18F]
FCA) was reported by De Lombaerde et al. [23] as
a promising probe to monitor altered hepatobilary
transport in vivo during drug development. Compared to
other PET tracers developed to study liver transporters
which are transported quite selectively by the OATPs and
MRP2 and BCRP [3, 4] bile acid-based tracers such as [18F]
LCATD, [18F]FCA and [11C]Cholylsarcosine are generally
handled by the same transporters involved in uptake and
eﬄux of endogenous bile acids (NTCP, OATP1B1,
OATP1B3, BSEP, and MRP2) [24–26], making them the
best candidates to study physiology and pathophysiology
of the hepatic bile acid transport in vivo [22, 23, 27].
As observed for the other bile acid-based [18F]ﬂuorine-
labelled PET tracer [18F]FCA [23], [18F]LCATD reached
a peak concentration in the liver in a very short time
(t_max � 135 seconds) in untreated animals.
Treatment with rifamycin SV reduced the maximum
activity recorded in the liver from 14.2± 0.8% to 10.2± 1.0%
and delayed t_max by 90 seconds, indicating an inhibitory
eﬀect of the drug on the transporters involved in the uptake
of [18F]LCATD. In rifamycin SV-treated rats the AUCliver
0–5min and the hepatic uptake clearance CLuptake,in vivo were
also signiﬁcantly reduced as a consequence of the eﬀect of
the drug on uptake transporters (Table 1). If compared with
the TAC obtained for control rats, rifamycin SV-treated rats
showed a less steep exponential decay during the phase
representing the excretion of the tracer from the hepato-
cytes. Consequently, the AUCliver 0–30min of rifamycin SV-
treated rats was higher than the AUCliver 0–30min of control
rats, while the AUCbile 0–10min of rifamycin SV-treated rats
was signiﬁcantly lower than the AUCbile 0–10min of control
rats, suggesting an inhibitory eﬀect on eﬄux transporters. It
is worth mentioning that although AUCliver 0–5min (which
describes the accumulation of the probe in the liver) and
CLuptake,in vivo (a kinetic parameter describing the transport
of probe substrate) are closely related, it is diﬃcult to
correlate them based on available information. Since uptake
transporters are inhibited by rifamycin SV, it is expected that
this will increase plasma/blood concentrations of the PET
tracer, while decreasing accumulation in liver reﬂected in
a decrease of AUCliver. ,is is conﬁrmed by the Kp liver
(tissue/plasma ratio) calculated for the three groups. Taken
together, this data are in accordance with the inhibitory
activity of rifamycin SV previously observed on both uptake
and canalicular transporters. In fact, rifamycin SV has been
shown to inhibit OATP1B1, OATP1B3, NTCP [16, 28], and
the ATP-dependent bile salt export pump (BSEP) [29, 30].
Inhibition of OATP1B1 and BSEP is expected to occur when
the serum-free concentration of rifamycin SV is higher than
its IC50 for these transporters. ,e reported IC50 values of
rifamycin SV for OATP1B1 and BSEP are, respectively,
0.2–0.4 µM [6, 16] and 6.3 µM [31], while a Ki value >63 µM
for NTCP has been reported [13]. ,e administered dose of
rifamycin SV was 62.5mg·Kg−1, and taking into account the
IC50 values indicated above, it is possible that rifamycin SV
plasma concentrations would be enough to inhibit
OATP1B1 and BSEP, whereas inhibition of NTCP may only
be partial. ,ese observations would be consistent with the
results of the PET imaging experiments. ,e administration
route of rifamycin SV and dose used in our protocol were
based on a previous study in which the structurally related
inhibitor rifampicin was used as hepatic transporters in-
hibitor in mice [32]. Inhibition of hepatic transport was seen
at a dose of 37.5mg·Kg−1 intraperitoneally and 9.37mg·Kg−1
intravenously [32]. ,is is in line with the observed in-
hibition of [18F]LCATD transport at the dose used in our
work (50mg·Kg−1 ip and 12.5mg·Kg−1 iv).
Postmortem analysis (50 minutes postinjection) of the
residual activity in liver, kidney, heart, and blood was also
consistent with the in vivo imaging results. In fact, a very low
residual tracer concentration was found in the liver in line
with the fast biliary clearance observed by PET imaging.
Very low activity was found in the kidneys (<0.1% of the
injected dose, comparable to other blood perfused organs
like the heart) and signiﬁcant diﬀerences (p< 0.05) were
found between the tracer concentrations in the blood of
control and rifamycin-treated rats, as a result of the drug-
induced impaired hepatic clearance.
Although we could not detect [18F]LCATD or any
radiometabolite in blood and liver extracts, radio-HPLC
analysis of intestine extracts of two animals from the con-
trol group showed a twin peak matching [18F]LCATD that
accounted for over 90% of the activity (see Figure S1,
Supplementary Materials), suggesting that the tracer is at
least 90% metabolically stable 50min postinjection.
Coadministration of sodium fusidate (30mg·Kg−1) de-
creased the liver uptake of [18F]LCATD, although to a lesser
extent compared to rifamycin SV: the maximum activity
found in the liver was reduced from 14.2± 0.8% to 11.4±
0.3% but t_max was not delayed in this case. ,e lower
AUCliver 0–5min and AUCliver 0–30min of fusidate-treated rats
relative to control rats (although the latter was not signif-
icant) indicated that the hepatocytes had been exposed to
lower amounts of PET tracer, as a likely result of the uptake
inhibition. Interestingly, the AUCbile 0–10min of fusidate-
treated rats was higher than the AUCbile 0–10min of con-
trol rats, even though the diﬀerence was not statistically
signiﬁcant. ,e CLint,bile was also higher than that of control
rats. Finally, signiﬁcant diﬀerences were found between the
tracer’s concentrations in the terminal blood sample of
control and fusidate-treated rats. All these results suggest
that at the administrated dose, sodium fusidate inhibits the
liver uptake of the tracer but not the canalicular eﬄux, which
instead seems to be stimulated by the presence of the drug.
,is might be explained by considering that, in previous
studies [33], fusidic acid (0.3–300 µM) was shown to
stimulate the MRP2 transporter (canalicular eﬄux) in vitro,
as indicated by the increased eﬄux of LTC4 (leucotriene C4)
using MRP2 transfected membrane vesicles. Many bile acid
salts are known to be transported by MRP2 [34] and, being
[18F]LCATD a bile acid analogue, it is possible that its
MRP2-mediated excretion might have been stimulated by
fusidic acid administration. However, for the scope of this
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study, we did not assess the involvement of MRP2 in the
canalicular eﬄux of [18F]LCATD, and we recognise that
future work should explore this aspect in greater detail.
,e eﬀect of sodium fusidate on the biliary transport has
been previously studied in vivo in rats, and an overall re-
duced biliary clearance of [3H]-cholyltaurine was observed
after administration of a 54mg·Kg−1 dose [35]. However, the
authors could not clarify if the eﬀect was due to a reduced
liver uptake of cholyltaurine or caused by a reduced cana-
licular eﬄux (thus increasing the hepatocyte exposure to the
drug), or both. In a more recent study, sodium fusidate was
shown to inhibit the hepatic uptake of rosuvastatin, via
inhibition of OATP1B1 and OATP1B3, when orally ad-
ministered in rats at a dose of 250mg·Kg−1 [17].
In our study, the administered dose of sodium fusidate
was 30mg·Kg−1, which is comparable to the dose previously
used by Bode (54mg·Kg−1 ip) [35] to study the eﬀect of
fusidate on cholyltaurine transport in the rat liver. Although
the actual plasma concentration could not be measured, the
administered dose of fusidate may be enough to inhibit
OATP1B1, BSEP, and NTCP. For these transporters, IC50
values of sodium fusidate have been reported to be in the
micromolar range: 1.6 to 35 µM for OATP1B1 [17, 18, 33],
3.8–11.5 μM for BSEP [31, 33], and 44 μM for NTCP [33].
,e higher CLint,bile observed for fusidate-treated rats could
be explained as the net eﬀect of fusidic acid on BSEP in-
hibition and MRP2 stimulation. ,e signiﬁcant diﬀerences
observed for fusidate-treated rats on AUCliver 0–5min, on the
radioactivity in the liver at 2 minutes postinjection and on
CLint,bile corroborate the hypothesis that [18F]LCATD, can
be used as a tracer to identify perturbation of hepatic uptake
and eﬄux transporters in vivo. However, in the case of
fusidic acid, further studies with transporter knock-out
rodent models may be necessary to unequivocally de-
lineate the net uptake and eﬄux inhibition and the stim-
ulation properties. Moreover, such knock-out rodent models
may help to understand the role of other eﬄux transporters
such as MATE1, BCRP, MRP2, and PgP in addition to BSEP
to the canalicular eﬄux of [18F]LCATD.
We can speculate that, if the objective of the experiment
is to determine whether a drug has potential for DDI,
continuous blood infusion of the investigational drug and/or
dose escalation may provide more conclusive information.
However, limitations due to altered tracer metabolism and
transporters expression induced by the administration of the
investigational drug, as well as reduced blood ﬂow due to
anaesthetic procedures may need to be considered.
5. Conclusion
In conclusion, we have shown that hepatic clearance of the
PET tracer [18F]LCATD (which had been previously
characterized in vitro) (6)] is signiﬁcantly modiﬁed in vivo,
in preclinical models (rat), by the coadministration of
rifamycin SV and sodium fusidate, which are known to
cause the inhibition of clinically relevant uptake and can-
alicular hepatic transporters.
Since [18F]LCATD can be easily prepared in a standard
fully automated radiosynthesis module [6] in any PET
radiochemistry laboratory (even in a non-PET-specialised
industrial environment) from commercially available
aqueous [18F]ﬂuoride solutions, we anticipate that this tracer
could be advantageously used in the safety evaluation of
investigational drugs early in the drug development phase.
Moreover, the use of bile acid analogues such as [18F]
LCATD, which are transported by bile acid transporters
NTCP and BSEP, could be tested as diagnostic agents, in
alternative to the very short lived [11C]cholylsarcosine, for
imaging pathophysiological hepatic conditions in patients.
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